Published in Clin Cancer Res on March 15, 2004
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol (2008) 2.04
PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Oncogene (2010) 1.77
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer (2007) 1.22
Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response (2010) 1.16
Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis. Langenbecks Arch Surg (2010) 1.10
Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: mechanistic insights and preclinical testing of therapeutic strategies. Clin Exp Metastasis (2009) 1.08
Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Mol Cancer Ther (2007) 1.05
Chronic oral exposure to bisphenol A results in a nonmonotonic dose response in mammary carcinogenesis and metastasis in MMTV-erbB2 mice. Environ Health Perspect (2011) 0.98
Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg (2007) 0.94
Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World J Gastroenterol (2008) 0.93
Current and emerging therapies for advanced adrenocortical carcinoma. Oncologist (2011) 0.92
Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms. Diabetes (2015) 0.89
Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int J Colorectal Dis (2005) 0.88
Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors. Cancer Manag Res (2012) 0.85
Targeted therapies for pancreatic cancer. Br Med Bull (2008) 0.84
Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. Br J Cancer (2016) 0.83
Elastomeric free-form blood vessels for interconnecting organs on chip systems. Lab Chip (2016) 0.81
Combining molecular targeted drugs to inhibit both cancer cells and activated stromal cells in gastric cancer. Neoplasia (2013) 0.81
A novel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer. Pharm Res (2013) 0.78
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 14.87
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06
Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA (2009) 3.83
Acute mesenteric ischemia: a vascular emergency. Dtsch Arztebl Int (2012) 2.70
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol (2010) 2.66
Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology (2009) 2.64
Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model. Histochem Cell Biol (2008) 2.39
Temporary intraoperative porto-caval shunt: useless or beneficial in piggy back liver transplantation? Transpl Int (2012) 2.17
Loss of liver transplant surgeons into alternate career paths. Transpl Int (2014) 2.04
The German hospital malnutrition study. Clin Nutr (2006) 1.93
Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut (2011) 1.84
Evaluation of clinical safety and beneficial effects of a fish oil containing lipid emulsion (Lipoplus, MLF541): data from a prospective, randomized, multicenter trial. Crit Care Med (2007) 1.80
Overture for growth hormone: requiem for interleukin-6? Crit Care Med (2007) 1.69
Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol (2007) 1.69
Endoscopic vacuum-assisted closure of anastomotic leakage following anterior resection of the rectum: a new method. Surg Endosc (2007) 1.68
Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation (2004) 1.68
Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation (2006) 1.64
Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant (2010) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie (2011) 1.57
Use of biosynthetic prosthesis (Omniflow II®) to replace infected infrainguinal prosthetic grafts--first results. Vasa (2012) 1.55
IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology (2008) 1.51
Shedding light on the elusive role of endothelial cells in cytomegalovirus dissemination. PLoS Pathog (2011) 1.51
Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg (2011) 1.44
Tumour nephrectomy with vena cava thrombus. BJU Int (2005) 1.43
High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice. J Gastroenterol Hepatol (2010) 1.42
The challenge of pancreatic anastomosis. Langenbecks Arch Surg (2008) 1.41
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 1.40
Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev (2007) 1.38
Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res (2008) 1.35
Immunological effects of laparoscopic vs open colorectal surgery: a prospective clinical study. Arch Surg (2005) 1.35
EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res (2009) 1.33
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer (2007) 1.30
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther (2007) 1.29
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res (2004) 1.28
Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res (2013) 1.27
Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther (2011) 1.26
Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res (2008) 1.26
Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol (2011) 1.25
Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest (2011) 1.25
A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int (2008) 1.24
Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer (2005) 1.22
Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo. Circulation (2008) 1.22
Insulin attenuates the systemic inflammatory response to thermal trauma. Mol Med (2002) 1.22
Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care (2009) 1.21
Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer (2003) 1.20
GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice. Clin Exp Metastasis (2003) 1.19
Vascular endothelial growth factor in esophageal cancer. J Surg Oncol (2004) 1.19
The prognostic value of lymph node ratio in a population-based collective of colorectal cancer patients. Ann Surg (2010) 1.18
Estimation of liver size for liver transplantation: the impact of age and gender. Liver Transpl (2004) 1.18
Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood (2005) 1.17
Cancer stem cells: how can we target them? Curr Med Chem (2008) 1.17
Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int (2008) 1.17
Comparison of laparoscopic vs. open access surgery in patients with rectal cancer: a prospective analysis. Dis Colon Rectum (2008) 1.17
Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation (2009) 1.16
Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. Int J Colorectal Dis (2009) 1.16
Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany. Cell Tissue Bank (2003) 1.16
EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol Chem (2009) 1.15
IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mol Ther (2012) 1.14
Deletion of Foxp3+ regulatory T cells in genetically targeted mice supports development of intestinal inflammation. BMC Gastroenterol (2012) 1.13
Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer (2010) 1.12
Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int (2005) 1.11
Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol (2008) 1.10
Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer (2008) 1.10
Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks Arch Surg (2009) 1.10
The intrinsic renal compartment syndrome: new perspectives in kidney transplantation. Transplantation (2010) 1.10
Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol (2012) 1.10
Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg (2009) 1.08
Does surgical resection of pulmonary metastases of head and neck cancer improve survival? Ann Surg Oncol (2008) 1.08